Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.

Journal of Neuro-oncology
Hyun-Cheol KangIn Ah Kim

Abstract

We investigated pseudoprogression (psPD) in patients with malignant gliomas treated with radiotherapy (RT) and maintenance temozolomide (TMZ) in terms of incidence, outcomes, and predictive and prognostic factors. We evaluated p53 overexpression by immunohistochemical analysis of thirty-five tumor samples as a predictor for psPD. The time to progression and overall survival were compared between subgroups, psPD versus early progression (ePD) versus nonprogression (nonPD). Eight patients developed psPD among eighteen patients with lesion enlargement at the first MRI scan, and the others were classified as ePD. The remaining stable or improved patients were classified as nonPD. All patients with psPD were alive at last follow-up (median follow-up period was 12 months; range 5.8-58.5 months). Overall survival of psPD patients was significantly higher than ePD patients (P < 0.01). There was no significant survival difference between the psPD group and nonPD group (P = 0.25). Seven (87.5%) of eight tumors with psPD showed p53 overexpression, as compared to 3 (30%) of the ten tumors with ePD (P = 0.03). Our study indicates that psPD following chemoradiotherapy with TMZ is associated with significantly better overall survival compared...Continue Reading

References

May 1, 1979·Journal of Neurosurgery·W F HoffmanC B Wilson
Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ G Cairncross
Sep 17, 1996·International Journal of Cancer. Journal International Du Cancer·H KöckD C Maneval
May 10, 2000·International Journal of Radiation Oncology, Biology, Physics·A TakahashiT Ohnishi
Apr 10, 2002·Journal of Neuropathology and Experimental Neurology·Matthias C SchmidtAndreas von Deimling
Jul 19, 2002·Cancer·Shoji ShiraishiYukitaka Ushio
Jan 30, 2004·International Journal of Cancer. Journal International Du Cancer·Nikolai N KhodarevRalph R Weichselbaum
Sep 30, 2004·International Journal of Cancer. Journal International Du Cancer·Takao WatanabeTakao Fukushima
Nov 13, 2004·Applied Immunohistochemistry & Molecular Morphology : AIMM·Karen CurtinWade S Samowitz
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Jun 28, 2005·Journal of Neuro-oncology·Chitra SarkarSubrata Sinha
May 13, 2006·Critical Reviews in Oncology/hematology·Benjamin Pierre BouchetCarlos María Galmarini
Sep 1, 2006·Journal of Neuro-oncology·Marc C ChamberlainAndrew E Sloan
Nov 15, 2007·International Journal of Cancer. Journal International Du Cancer·Dorothee WiewrodtBernd Kaina
Feb 15, 2008·AJNR. American Journal of Neuroradiology·J W HensonG J Harris
May 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alba A BrandesMario Ermani
May 3, 2008·The Lancet Oncology·Dieta BrandsmaMartin J van den Bent
Dec 23, 2008·Cancer Genetics and Cytogenetics·Emilia Jesien-LewandowiczRadzisław Kordek
Jun 23, 2009·Cancer Investigation·Jamal ShamsaraJavad Behravan

❮ Previous
Next ❯

Citations

Mar 15, 2011·American Journal of Clinical Oncology·Erkan TopkanBerrin Pehlivan
Apr 3, 2013·Expert Review of Neurotherapeutics·Tim J KruserH Ian Robins
Nov 2, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Christos SachpekidisJessica C Hassel
Dec 11, 2013·Expert Opinion on Investigational Drugs·Isabel Arrillaga-RomanyPatrick Y Wen
Sep 24, 2016·Expert Review of Anticancer Therapy·Jean-Guy BelliveauDavid R Macdonald
Apr 14, 2015·Proteome Science·Peng ZhangLiwei Zhang
Nov 2, 2019·British Journal of Cancer·Juliana Müller BarkChamindie Punyadeera

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.